Objective measurement in clinical care of patients with Parkinson’s disease
Objective: To establish whether using the Parkinson's KinetiGraph™ which provides objective measures in activities of daily living, helps identify unknown poorly controlled patients with Parkinson's…The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA
Objective: The primary endpoint of clinical progression is measured by change in the total UPDRS score between baseline and 1) after 52 weeks of study…Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study
Objective: To evaluate the validity of motor phenotype classification in response to dopaminergic agents in moderate to advanced Parkinson's disease (PD) patients enrolled in the…Whole body vibration therapy with exercise enhances motor function and improves quality of life in Parkinson’s disease
Objective: To evaluate the short term effects of whole body vibration and exercise in patients with Parkinson's disease on overall quality of life, gait, tremor,…Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease
Objective: This presentation highlights a new precompetitive consortium based strategy for the successful development of regulatory-endorsed biomarkers and quantitative drug development platforms targeted at the…Can hospital admissions predict mortality in Parkinson’s?
Objective: Profile patients with Parkinson's who experience inpatient care. Assess the impact of admissions to hospital and evaluate readmissions and mortality rates. Background: People with…A randomized clinical trial of atomoxetine treatment for mild cognitive impairment (MCI) in Parkinson’s disease (PD)
Objective: To evaluate (1) safety and tolerability of ATM and (2) effects of ATM on attention and executive functioning in PD- MCI after 10 weeks…STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort
Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…Active movement discrimination of the ankle in Parkinson’s disease
Objective: To determine (1) whether people with Parkinson's disease (PD) experience an impaired sense of proprioception in the ankles and (2) if this relates to…Effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson’s disease: 7- year follow-up
Objective: To evaluate the long-term outcome of unilateral STN DBS in highly asymmetric patients with PD. Background: Unilateral STN DBS is suggested to be a…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 207
- Next Page »